Genital Chlamydia trachomatis Seroprevalence and Uterine Fibroid Development: Cohort Study of Young African-American Women
Abstract
:1. Introduction
2. Materials and Methods
2.1. Chlamydia Measurement
2.2. Fibroid Measurement
2.3. Covariates
2.4. Statistical Analysis
2.4.1. Fibroid Incidence
2.4.2. Fibroid Growth
2.5. Sensitivity Analyses
3. Results
3.1. Fibroid Incidence
3.2. Fibroid Growth
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Cardozo, E.R.; Clark, A.D.; Banks, N.K.; Henne, M.B.; Stegmann, B.J.; Segars, J.H. The estimated annual cost of uterine leiomyomata in the United States. Am. J. Obstet. Gynecol. 2012, 206, 211.e1–219.e9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Laughlin, S.K.; Baird, D.D.; Savitz, D.A.; Herring, A.H.; Hartmann, K.E. Prevalence of uterine leiomyomas in the first trimester of pregnancy: An ultrasound-screening study. Obstet. Gynecol. 2009, 113, 630–635. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Laughlin, S.K.; Schroeder, J.C.; Baird, D.D. New directions in the epidemiology of uterine fibroids. Semin. Reprod. Med. 2010, 28, 204–217. [Google Scholar] [CrossRef] [Green Version]
- Baird, D.D.; Dunson, D.B.; Hill, M.C.; Cousins, D.; Schectman, J.M. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am. J. Obstet. Gynecol. 2003, 188, 100–107. [Google Scholar] [CrossRef] [PubMed]
- Jacoby, V.L.; Fujimoto, V.Y.; Giudice, L.C.; Kuppermann, M.; Washington, A.E. Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am. J. Obstet. Gynecol. 2010, 202, 514–521. [Google Scholar] [CrossRef] [Green Version]
- Wechter, M.E.; Stewart, E.A.; Myers, E.R.; Kho, R.M.; Wu, J.M. Leiomyoma-related hospitalization and surgery: Prevalence and predicted growth based on population trends. Am. J. Obstet. Gynecol. 2011, 205, 492.e1–492.e5. [Google Scholar] [CrossRef] [Green Version]
- Marsh, E.E.; Bulun, S.E. Steroid hormones and leiomyomas. Obstet. Gynecol. Clin. N. Am. 2006, 33, 59–67. [Google Scholar] [CrossRef]
- Mirin, A.A. Gender Disparity in the Funding of Diseases by the U.S. National Institutes of Health. J. Womens Health 2021, 30, 956–963. [Google Scholar] [CrossRef] [PubMed]
- Wise, L.A.; Palmer, J.R.; Harlow, B.L.; Spiegelman, D.; Stewart, E.A.; Adams-Campbell, L.L.; Rosenberg, L. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: A prospective study. Am. J. Epidemiol. 2004, 159, 113–123. [Google Scholar] [CrossRef] [Green Version]
- Marshall, L.M.; Spiegelman, D.; Goldman, M.B.; Manson, J.E.; Colditz, G.A.; Barbieri, R.L.; Stampfer, M.J.; Hunter, D.J. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil. Steril. 1998, 70, 432–439. [Google Scholar] [CrossRef]
- Lumbiganon, P. Protective Effect of Depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: A multicentre case—Control study. Br. J. Obstet. Gynaecol. 1996, 103, 909–914. [Google Scholar] [CrossRef]
- Harmon, Q.E.; Baird, D.D. Use of depot medroxyprogesterone acetate and prevalent leiomyoma in Young African American women. Hum. Reprod. 2015, 30, 1499–1504. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Witherspoon, J.T.; Butler, V.W. The etiology of uterine fibroids, with special reference to the frequency of their occurrence in the Negro: An hypothesis. Surg. Gynecol. Obstet. 1934, 58, 57–61. [Google Scholar]
- Leppert, P.C.; Catherino, W.H.; Segars, J.H. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am. J. Obstet. Gynecol. 2006, 195, 415–420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wegienka, G. Are uterine leiomyoma a consequence of a chronically inflammatory immune system? Med. Hypotheses 2012, 79, 226–231. [Google Scholar] [CrossRef] [PubMed]
- Moore, K.R.; Smith, J.S.; Cole, S.R.; Dittmer, D.P.; Schoenbach, V.J.; Baird, D.D. Chlamydia trachomatis Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. Am. J. Epidemiol. 2018, 187, 278–286. [Google Scholar] [CrossRef] [PubMed]
- Horner, P.J.; Wills, G.S.; Reynolds, R.; Johnson, A.M.; Muir, D.A.; Winston, A.; Broadbent, A.J.; Parker, D.; Mcclure, M.O. Effect of time since exposure to Chlamydia trachomatison chlamydia antibody detection in women: A cross-sectional study. Sex. Transm. Infect. 2013, 89, 398–403. [Google Scholar] [CrossRef] [PubMed]
- Marrazzo, J.M. Management of women with cervicitis. Clin. Infect. Dis. 2007, 44 (Suppl. S3), S102–S110. [Google Scholar] [CrossRef] [Green Version]
- Jones, R.B. Recovery of Chlamydia trachomatis from the endometrium of women at risk for chlamydial infection. Am. J. Obstet. Gynecol. 1986, 155, 35–39. [Google Scholar] [CrossRef]
- Kiviat, N.B.; Wolner-Hanssen, P.; Eschenbach, D.A.; Wasserheit, J.N.; Paavonen, J.A.; Bell, T.A.; Critchlow, C.W.; Stamm, W.E.; Moore, D.E.; Holmes, K.K. Endometrial histopathology in patients with culture-proved upper genital tract infection and laparoscopically diagnosed acute salpingitis. Am. J. Surg. Pathol. 1990, 14, 167–175. [Google Scholar] [CrossRef]
- Faerstein, E.; Szklo, M.; Rosenshein, N.B. Risk factors for uterine leiomyoma: A practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am. J. Epidemiol. 2001, 153, 11–19. [Google Scholar] [CrossRef] [PubMed]
- Moore, K.R.; Cole, S.R.; Dittmer, D.P.; Schoenbach, V.J.; Smith, J.S.; Baird, D.D. Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women. J. Womens Health 2015, 24, 489–495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baird, D.D.; Harmon, Q.E.; Upson, K.; Moore, K.R.; Barker-Cummings, C.; Baker, S.; Cooper, T.; Wegienka, G. A prospective, ultrasound-based study to evaluate risk factors for uterine fibroid incidence and growth: Methods and results of recruitment. J. Womens Health (2002) 2015, 24, 907–915. [Google Scholar] [CrossRef]
- Wang, S.P. Human serology in Chlamydia trachomatis infection with microimmunofluorescence. J. Infect. Dis. 1974, 130, 388–397. [Google Scholar] [CrossRef] [PubMed]
- Laughlin, S.K.; Herring, A.H.; Savitz, D.A.; Olshan, A.F.; Fielding, J.R.; Hartmann, K.E.; Baird, D.D. Pregnancy-related fibroid reduction. Fertil. Steril. 2010, 94, 2421–2423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baird, D.D.; Patchel, S.A.; Saldana, T.M.; Umbach, D.M.; Cooper, T.; Wegienka, G.; Harmon, Q.E. Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African Americans. Am. J. Obstet. Gynecol. 2020, 223, 402.e401–402.e418. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018. 2019. Available online: https://doi.org/10.15620/cdc.79370 (accessed on 10 December 2021).
- Farley, T.A.; Cohen, D.A.; Elkins, W. Asymptomatic sexually transmitted diseases: The case for screening. Prev. Med. 2003, 36, 502–509. [Google Scholar] [CrossRef]
- Petersen, M.R.; Patel, E.U.; Grabowski, M.K.; Gaydos, C.A.; Quinn, T.C.; Tobian, A.A.R. Seroprevalence of Chlamydia trachomatis among Female Adults in the United States: The National Health and Nutrition Examination Surveys. Clin. Infect. Dis. 2021, 73, e629–e637. [Google Scholar] [CrossRef]
- Lunny, C.; Taylor, D.; Hoang, L.; Wong, T.; Gilbert, M.; Lester, R.; Krajden, M.; Ogilvie, G. Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis. PLoS ONE 2015, 10, e0132776. [Google Scholar] [CrossRef]
- Kersh, E.N.; Shukla, M.; Raphael, B.H.; Habel, M.; Park, I. At-Home Specimen Self-Collection and Self-Testing for Sexually Transmitted Infection Screening Demand Accelerated by the COVID-19 Pandemic: A Review of Laboratory Implementation Issues. J. Clin. Microbiol. 2021, 59, e0264620. [Google Scholar] [CrossRef]
- Gaydos, C.A.; Dwyer, K.; Barnes, M.; Rizzo-Price, P.A.; Wood, B.J.; Flemming, T.; Hogan, M.T. Internet-based screening for Chlamydia trachomatis to reach non-clinic populations with mailed self-administered vaginal swabs. Sex. Transm. Dis. 2006, 33, 451–457. [Google Scholar] [CrossRef] [PubMed]
Chlamydia Serostatus | Total | ||
---|---|---|---|
Baseline Variable | No n = 476 n (%) | Yes n = 682 n (%) | 1158 |
Age (years): median (IQR) | 29 (26–32) | 29 (26–32) | |
Income | |||
<20 K | 173 (37) | 360 (53) | 533 |
20–<50 K | 199 (42) | 234 (35) | 433 |
50 K+ | 102 (22) | 79 (12) | 181 |
Missing (n = 11) | |||
Education | |||
≤High School | 76 (16) | 193 (28) | 269 |
>High School | 400 (84) | 488 (72) | 888 |
Missing (n = 1) | |||
Employed | |||
No | 308 (65) | 384 (56) | 692 |
Yes | 168 (35) | 296 (44) | 464 |
Missing (n = 2) | |||
Body Mass Index 1 | |||
<25 | 127 (27) | 108 (16) | 235 |
25–29 | 90 (19) | 157 (23) | 247 |
30–34 | 92 (19) | 124 (18) | 216 |
35–40 | 76 (16) | 113 (17) | 189 |
40+ | 91 (19) | 180 (26) | 271 |
Heavy Alcohol Use (past year) 2 | |||
No | 403 (85) | 530 (78) | 933 |
Yes | 73 (15) | 152 (22) | 225 |
Currently Married | |||
No | 324 (68) | 511 (75) | 835 |
Yes | 152 (32) | 171 (25) | 323 |
Current Use of Oral Contraception | |||
No | 410 (86) | 622 (91) | 1032 |
Yes | 66 (14) | 60 (9) | 126 |
Recent Birth | |||
<5 years | 157 (33) | 235 (34) | 392 |
5+ years or no birth | 319 (67) | 447 (66) | 766 |
Number of Births Prior to Last | |||
0–1 Birth | 397 (83) | 507 (74) | 904 |
2 Births | 57 (12) | 87 (13) | 144 |
3+ Births | 22 (5) | 88 (13) | 110 |
Depo-Provera Use (Last 2 Years) | |||
No | 426 (90) | 615 (90) | 1041 |
Yes | 50 (11) | 67 (10) | 117 |
Age at Menarche (years) | |||
≤10 | 71 (15) | 125 (18) | 196 |
Age 11 | 99 (21) | 139 (20) | 238 |
Age 12 | 149 (31) | 174 (26) | 323 |
Age 13 | 73 (15) | 115 (17) | 188 |
14+ | 84 (18) | 129 (19) | 213 |
Current Smoker | |||
No | 422 (89) | 514 (75) | 936 |
Yes | 54 (11) | 168 (25) | 222 |
Number of Sex Partners | |||
0–5 | 194 (42) | 145 (21) | 339 |
6–10 | 132 (28) | 200 (29) | 332 |
≥11 | 139 (30) | 335 (49) | 474 |
Missing (n = 13) | |||
Age at 1st Intercourse (years) | |||
≤4 | 92 (20) | 246 (36) | 338 |
15–16 | 151 (32) | 258 (38) | 409 |
≥17 3 | 222 (48) | 175 (26) | 397 |
Missing (n = 14) | |||
HSV-2 Seropositive | |||
No | 318 (67) | 288 (42) | 606 |
Yes | 157 (33) | 392 (58) | 549 |
Missing (n = 3) |
Counts across 3 Follow-Up Intervals | Incident Fibroids | Unadjusted HR (95% CI) | Adjusted 1 HR (95% CI) | |||
---|---|---|---|---|---|---|
Chlamydia Serology | Women | Visits | n | % of Women | ||
Seronegative | 476 | 1185 | 119 | 25 | 1.00 (ref) | 1.00 (ref) |
Seropositive | 682 | 1699 | 158 | 23 | 0.9 (0.72, 1.16) | 1.0 (0.79, 1.29) |
Chlamydia Serology | Growth Measurements 1 n = 1254 | Adjusted 2 Estimated Percent Difference in Growth/18 Months (95% CI) |
---|---|---|
Seronegative | 645 | |
Seropositive | 609 | 4.4% (−5.02, 14.64) 3 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Moore, K.; Baird, D. Genital Chlamydia trachomatis Seroprevalence and Uterine Fibroid Development: Cohort Study of Young African-American Women. Microorganisms 2022, 10, 10. https://doi.org/10.3390/microorganisms10010010
Moore K, Baird D. Genital Chlamydia trachomatis Seroprevalence and Uterine Fibroid Development: Cohort Study of Young African-American Women. Microorganisms. 2022; 10(1):10. https://doi.org/10.3390/microorganisms10010010
Chicago/Turabian StyleMoore, Kristen, and Donna Baird. 2022. "Genital Chlamydia trachomatis Seroprevalence and Uterine Fibroid Development: Cohort Study of Young African-American Women" Microorganisms 10, no. 1: 10. https://doi.org/10.3390/microorganisms10010010